Search

Your search keyword '"Cahlin, C."' showing total 2 results
Start Over Author "Cahlin, C." Language swedish
2 results on '"Cahlin, C."'

1. [Liver transplantation in metastatic neuroendocrine tumors. Symptom-free intervals and cure possible].

Author

Ahlman H, Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, and Wängberg B

Subjects
Adult, Biomarkers, Tumor analysis, Carcinoid Tumor mortality, Carcinoid Tumor secondary, Carcinoid Tumor surgery, Female, Humans, Liver Neoplasms mortality, Liver Neoplasms secondary, Male, Middle Aged, Neoplasm Recurrence, Local diagnosis, Neuroendocrine Tumors mortality, Neuroendocrine Tumors secondary, Pancreatic Neoplasms mortality, Pancreatic Neoplasms secondary, Pancreatic Neoplasms surgery, Risk Factors, Survival Analysis, Tomography, X-Ray Computed, Treatment Outcome, Liver Neoplasms surgery, Liver Transplantation methods, Neuroendocrine Tumors surgery
Published
2007

2. [Treatment of patients with liver metastases from colorectal cancer. More patients can benefit from the treatment!].

Author

Lindnér P, Cahlin C, Friman S, Hafström L, Rizell M, and Olausson M

Subjects
Antineoplastic Agents therapeutic use, Chemotherapy, Adjuvant, Colorectal Neoplasms drug therapy, Colorectal Neoplasms mortality, Follow-Up Studies, Hepatectomy, Humans, Liver Neoplasms drug therapy, Liver Neoplasms mortality, Liver Neoplasms surgery, Prognosis, Survival Rate, Treatment Outcome, Colorectal Neoplasms surgery, Liver Neoplasms secondary
Abstract

Liver resection for liver metastases goes with 30-40% five years survival. It is estimated that 10% of patients with liver metastases can be subjected to liver resection. In the Västra Götaland region, this number is not achieved. In the present material of 147 patients, the postoperative mortality was 2.7%. Five years survival was 33%. Preoperative chemotherapy and preoperative porta embolisation have extended the indication for liver resection. Reresection after recurrence limited to the liver should be considered in selected cases. Ablative measures are under development and should be evaluated in clinical trials. New chemotherapeutic drugs (oxaliplatin, irinotecan) with improved recurrence rate but with limited gain in survival might have an impact as adjuvant therapy. A surgeon with liver surgery competence should see patients with a presumably resectable cancer.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results